for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Starpharma Holdings Limited

SPL.AX

Latest Trade

0.78AUD

Change

0.01(+1.31%)

Volume

218,718

Today's Range

0.74

 - 

0.78

52 Week Range

0.62

 - 

1.45

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.77
Open
0.76
Volume
218,718
3M AVG Volume
7.18
Today's High
0.78
Today's Low
0.74
52 Week High
1.45
52 Week Low
0.62
Shares Out (MIL)
372.48
Market Cap (MIL)
285.01
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

更多

Starpharma Holdings Announces Completion Of Phase 1 Trial For DEP Cabazitaxel

Starpharma Holdings Says Co Granted Marketing Approval For Vivagel Condom In Europe

Starpharma Holdings Says Vivagel BV Has Been Launched In UK

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Starpharma Holdings Limited

Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses. The Company’s development programs, including VivaGel portfolio and DEP drug delivery. The Company’s DEP drug delivery, which includes DEP docetaxel, DEP cabazitaxel, DEP irinotecan and Targeted-DEP. It develops and commercializes dendrimer nanotechnology across various applications, including sexual health, drug delivery for pharmaceuticals, animal health, coatings and inks, crop protection, diagnostics and research reagents, cosmetics and water treatment. Its products are based on VivaGel (SPL7013, astodrimer sodium), a dendrimer, which has antimicrobial properties. It has both partnered and internal programs in drug delivery.

Contact Info

4-6 Southampton Crescent

MELBOURNE, VIC

3067

Australia

+61.3.85322700

http://www.starpharma.com

Executive Leadership

Robert Bain Thomas

Independent Non-Executive Chairman of the Board

Jacinth K. Fairley

Chief Executive Officer, Executive Director

Nigel J. Baade

Chief Financial Officer, Company Secretary

David J. Owen

Vice President - Research

Jeremy R. Paull

Vice President - Development and Regulatory Affairs

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (AUD)

2017

0.020

2018

-0.028

2019

-0.040

2020(E)

-0.037
Price To Earnings (TTM)
--
Price To Sales (TTM)
36.87
Price To Book (MRQ)
7.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.92
LT Debt To Equity (MRQ)
3.36
Return on Investment (TTM)
-29.41
Return on Equity (TTM)
-26.00

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up